logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Vertex Pharmaceuticals Announced Positive Results from its Non-Opioid Product VX-548

Vertex Pharmaceuticals Positive Results for VX-548 Today, Vertex Pharmaceuticals ( VRTX ) announced positive results from its Phase 3 program for the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double- blind, placebo-controlled, pivotal trials, one...

Read More

January 30, 2024

0

Beam Therapeutics Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

Beam Therapeutics in the NEWS Beam Therapeutics ( BEAM ) announced that Eli Lilly ( LLY ) has agreed to acquire certain rights under Beam’s amended collaboration and license agreement with Verve Therapeutics (Verve) , including Beam’s opt-in rights to...

Read More

October 31, 2023

0

Vera Therapeutics to Participate in Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and More

Vera Therapeutics to Participate in Guggenheim Healthcare Talks February 2, 2024, Vera Therapeutics, Inc. ( VERA ) announced that the Company’s management team will participate in the 6th Annual Guggenheim Biotechnology Conference, which is taking place in New York in...

Read More

February 2, 2024

0

Good News for CRISPR Therapeutics and Vertex Pharmaceuticals

CRISPR Therapeutics and Vertex Pharmaceuticals NEWS CRISPR Therapeutics ( CRSP ) announced the completion of the U.S. Food and Drug Administration’s ( FDA ) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of...

Read More

November 1, 2023

0

Published in Nature Communications: MiNK Therapeutics' AgenT-797 Demonstrates Promising Results in the Treatment of Severe Acute Respiratory Distress

MiNK Therapeutics in the NEWS  Today, February 6, 2024,  MiNK Therapeutics ( INKT ) announced the publication of the results in Nature Communications from phase 1/2 study of agenT-797 in patients with moderate-to-severe acute respiratory distress ( ARDS ) secondary to SARS-CoV-2....

Read More

February 6, 2024

0

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

ImmunoGen in the NEWS Immunogen ( IMGN ) - a developer of  antibody-drug conjugates ( ADCs ) for cancer treatment , today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023. From...

Read More

November 2, 2023

0

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Madrigal Pharmaceuticals Publication in the New England Journal of Medicine Resmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial Detailed analyses reinforce the safety profile of resmetirom...

Read More

February 8, 2024

0

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association Scientific Sessions 2023

CRISPR Therapeutics Data Presentation Announcement CRISPR Therapeutics ( CRSP ) today announced preclinical data from the Company’s investigational programs for the treatment of cardiovascular disease at the American Heart Association ( AHA ) Scientific Sessions 2023. The data will be...

Read More

November 6, 2023

0

Vertex Pharmaceuticals: EC Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVYTM, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

European Commission Grants Conditional Marketing to Vertex Pharmaceuticals CASGEVY Tuesday Feb 13, 2024, Vertex Pharmaceuticals ( VRTX ) announced that the European Commission has granted conditional marketing authorization to CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy. CASGEVY is being...

Read More

February 13, 2024

0

Two Pieces of News from CRISPR Therapeutics Today

Crispr Therapeutics First NEWS As we learned from Vertex Pharmaceuticals ( VRTX ) in an earlier, posted press release about the European approval, Crispr Therapeutics ( CRSP ) has also announced the same breakthrough news that the European Commission has...

Read More

February 13, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 149
  • 150
  • 151
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy